Pembrolizumab-MK-3475-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEPembrolizumabCat.No.:HY-P9902CASNo.:1374853-91-4Synonyms:MK-3475;Lambrolizumab;Keytruda分⼦量:146266.23作⽤靶点:PD-1/PD-L1作⽤通路:Immunology/Inflammation储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Pembrolizumab(MK-3475)⼀种⼈化IgG4抗体，为PD-1的抑制剂，⽤于癌症免疫的研究。IC50&TargetIC50:0.6nM(PD-1)体外研究Pembrolizumab(MK-3475)increasesthesecretionofcytokinesIFN-γ,TNF-αandtheapoptoticcelldeathofA549cells.PembrolizumabPembrolizumab(MK-3475)improvestheαROR1-CART-mediatedcytotoxicity,andreducestumorigenesisintheco-culturedαROR1-CARTandA549cellsbyblockingPD-1::PD-L1interactioninαROR1-CARTcells[2].CellCytotoxicityAssay[2]CellLine:αROR1-CARTandA549cellsConcentration:10μg/mLIncubationTime:AddingPembrolizumabafterA549-Red-Fluccellspreconditionedinelevatedpressure(+100mmHg)for7days.Result:EnhancedαROR1‑CARTkillingofA549lungcancercellsunderelevatedpressure.ApoptosisAnalysis[2]CellLine:A549cellsConcentration:10μg/mL1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEIncubationTime:Result:IncreasedtheapoptoticcelldeathinA549cells,andimprovetheαROR1-CART-mediatedcytotoxicity.体内研究PembrolizumabinhibitstumorsizeinA549xenograftmicepretreatedbypressure[2].AnimalModel:Six-week-oldmaleBALB/cathymicnudemice[2]Dosage:5mg/kgAdministration:Pembrolizumab(5mg/kg;Intravenousinjection;Once)Result:ReducedtumorigenesisinαROR1-CARTcellsandco-culturedwithA549cells.户使⽤本产品发表的科研⽂献•JImmunotherCancer.2022Mar;10(3):e003667.•CellDeathDis.2021May9;12(5):465.•CancerImmunolImmunother.2021Nov12.•ResearchSquarePrint.2022Aug.•ACSApplBioMater.2020Sep21.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ZhenglinOu,etal.PressureincreasesPD‑L1expressioninA549lungadenocarcinomacellsandcausesresistancetoanti‑ROR1CARTcell‑mediatedcytotoxicity,SciRep[2].AmitaPatnaik,etal.PhaseIStudyofPembrolizumab(MK-3475;Anti–PD-1MonoclonalAntibody)inPatientswithAdvancedSolidTumors.ClinCancerRes.2015Oct1;21(19):4286-93.[3].SchachterJ,etal.Pembrolizumabversusipilimumabforadvancedmelanoma:finaloverallsurvivalresultsofamulticentre,randomised,open-labelphase3study(KEYNOTE-006).Lancet.2017Aug16.pii:S0140-6736(17)31601-X.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.For